ArticleIranian journal of medical sciences2015
Survival analysis and its associated factors of Beta thalassemia major in hamadan province.
Article in Iranian journal of medical sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 27 citations in OpenAlex.
- Factors Contributing to Improved Bone Mineral Density in Patients With Transfusion-Dependent Thalassemia.The Kaohsiung journal of medical sciences · 2026Article
- Epidemiology of the Incidence, Prevalence, and Mortality of Thalassemia in Iran: A Secondary Analysis of Global Burden of Disease 2019.Health science reports · 2025Article
- Changing patterns in the epidemiology of β-thalassemia.European journal of haematology · 2020Review
- Effects of Aquatic Exercise on Dimensions of Quality of Life and Blood Indicators in Patients with Beta-Thalassemia Major.International journal of preventive medicine · 2020Article
- Association of frequency of hereditary hemochromatosis (HFE) gene mutations (H63D and C282Y) with iron overload in beta-thalassemia major patients in Pakistan.Saudi medical journal · 2019Article
- Alpha-Thalassemia in North Morocco: Prevalence and Molecular Spectrum.BioMed research international · 2019Article
- The survival rate of patients with beta-thalassemia major and intermedia and its trends in recent years in Iran.Epidemiology and health · 2018Article
- Trends in 5-, 10-, 20-, and 30-year survival rates of beta-thalassemia patients in Southern Iran, 1995-2016: A retrospective cohort study.Journal of public health research · 2017Article
- Exploring Iranian β-Thalassemia major patients' perception of barriers and facilitators of adherence to treatment: A qualitative study.Electronic physician · 2017Article
- Survival analysis of thalassemia major patients using Cox, Gompertz proportional hazard and Weibull accelerated failure time models.Medical journal of the Islamic Republic of Iran · 2017Article
- Poor quality of life as a predictor of survival among thalassemia patients in Iran.Epidemiology and health · 2017Article
- Analysis of survival data in thalassemia patients in Shiraz, Iran.Epidemiology and health · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere currently is a lack of knowledge about the long-term survival of patients with beta thalassemia (BT), particularly in regions with low incidence of the disease. The aim of the present study was to determine the survival rate of the patients with BT major and the factors associated with the survival time.
methodsThis retrospective cohort study was performed in Hamadan province, located in the west of Iran. The study included patients that referred to the provincial hospitals during 16 year period from 1997 to 2013. The follow up of each subject was calculated from the date of birth to the date of death. Demographic and clinical data were extracted from patients' medical records using a checklist. Statistical analysis included the Kaplan-Meier method to analyze survivals, log-rank to compare curves between groups, and Cox regression for multivariate prognostic analysis.
resultsA total of 133 patients with BT major were enrolled, 54.9% of whom were male and 66.2% were urban. The 10-, 20- and 30-year survival rate for all patients were 98.3%, 88.4% and 80.5%, respectively. Based on hazard ratio (HR), we found that accompanied diseases (P=0.01), blood type (P=0.03) and residency status (P=0.01) were significant predictors for the survival time of patients.
conclusionThe survival rate of BT patients has improved. Future researches such as prospective designs are required for the estimation of survival rate and to find other prognostic factors, which have reliable sources of data.
Indexed as
Identifiers
25999623PMC4430885W1589815237What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.